Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants
Giovanni Ostuzzi, Federico Bertolini, Federico Tedeschi, et al.
World Psychiatry (2022) Vol. 21, Iss. 2, pp. 295-307
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development
Toby Pillinger, Oliver Howes, Christoph U. Correll, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 11, pp. 860-876
Open Access | Times Cited: 63
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
Long‐term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta‐analysis
Stefan Leucht, Johannes Schneider‐Thoma, Angelika Burschinski, et al.
World Psychiatry (2023) Vol. 22, Iss. 2, pp. 315-324
Open Access | Times Cited: 44
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 402-409
Open Access | Times Cited: 68
Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis
Giovanni Ostuzzi, Giovanni Vita, Federico Bertolini, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 8, pp. 614-624
Closed Access | Times Cited: 45
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 3, pp. 197-208
Open Access | Times Cited: 29
Psychotherapies for Generalized Anxiety Disorder in Adults
Davide Papola, Clara Miguel, Mariacristina Mazzaglia, et al.
JAMA Psychiatry (2023) Vol. 81, Iss. 3, pp. 250-250
Open Access | Times Cited: 25
Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis
Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, et al.
Molecular Psychiatry (2024)
Open Access | Times Cited: 11
Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy
Giulia Turri, Giovanni Ostuzzi, Giovanni Vita, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2414702-e2414702
Open Access | Times Cited: 10
Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia
Giulia Maria Giordano, Pasquale Pezzella, Armida Mucci, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 9
Psychosis superspectrum II: neurobiology, treatment, and implications
Roman Kotov, William T. Carpenter, David C. Cicero, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 5, pp. 1293-1309
Closed Access | Times Cited: 9
Identification and treatment of individuals with childhood-onset and early-onset schizophrenia
Christoph U. Correll, Celso Arango, Birgitte Fagerlund, et al.
European Neuropsychopharmacology (2024) Vol. 82, pp. 57-71
Open Access | Times Cited: 9
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
Salvatore Cipolla, Flora Delli Carpini, Pierluigi Catapano, et al.
Clinics and Practice (2025) Vol. 15, Iss. 3, pp. 55-55
Open Access | Times Cited: 1
Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
Heidi Taipale, Antti O. Tanskanen, Jari Tiihonen
American Journal of Psychiatry (2023) Vol. 180, Iss. 5, pp. 377-385
Closed Access | Times Cited: 20
A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia
Gaia Sampogna, Matteo Di Vincenzo, Luigi Giuliani, et al.
Brain Sciences (2023) Vol. 13, Iss. 11, pp. 1577-1577
Open Access | Times Cited: 18
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Stefan Leucht, Josef Priller, John M. Davis
American Journal of Psychiatry (2024) Vol. 181, Iss. 10, pp. 865-878
Closed Access | Times Cited: 8
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Marco Solmi, Alessandro Miola, Federico Capone, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1249-1269
Closed Access | Times Cited: 6
The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in people with schizophrenia
Paola Rucci, Edoardo Caporusso, Francesco Sanmarchi, et al.
BJPsych Open (2023) Vol. 9, Iss. 5
Open Access | Times Cited: 14
Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis
Giovanni Vita, Angelantonio Tavella, Giovanni Ostuzzi, et al.
Therapeutic Advances in Psychopharmacology (2024) Vol. 14
Open Access | Times Cited: 5
The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
Andrea Fiorillo, Gaia Sampogna, Umberto Albert, et al.
Brain Sciences (2024) Vol. 14, Iss. 3, pp. 225-225
Open Access | Times Cited: 4
Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia
Christoph U. Correll, Karen L. Johnston, Ibrahim Turkoz, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2421495-e2421495
Open Access | Times Cited: 4
Real-World Effectiveness of Long-Acting Injectable and Oral Antipsychotic Agents in US Medicare Patients with Schizophrenia
Pengxiang Li, Zhi Geng, Carmela Benson, et al.
Advances in Therapy (2025) Vol. 42, Iss. 2, pp. 1251-1264
Open Access
Continuous Dopamine D2 Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia
Jari Tiihonen, Antti Tanskanen, Marco Solmi, et al.
American Journal of Psychiatry (2025), pp. 00-00
Closed Access
Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review
Antonio Melillo, Edoardo Caporusso, Giulia Maria Giordano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 7095-7095
Open Access | Times Cited: 10
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders
Khasan Ibragimov, Gregory Keane, Cristina Carreño Glaría, et al.
Cochrane library (2024) Vol. 2024, Iss. 7
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top